Bladder cancer trials in Japan

In Japan 28 Also abroad 625

28 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Where
Chiba, Nagoya, Tokyo
Age
18 years and over
People
677 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT05614739 · EU 2022-502755-59-00
Phase 1Taking people
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
Chūōku, Kashiwa, Chiba, Kōtō City, Nagoya
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
Phase 2Taking people
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Chuo Ku, Kashiwa, Koto-ku, Nagoya, Sakai, Sapporo
Age
18 years and over
People
111 worldwide
Run by
Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00
Phase 3Taking people
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Where
Amagasaki, Kawasaki, Kobe, Kumamoto, Osaka, Ōta-ku, Saitama, Wakayama, Yokohama, Yokosuka
Age
18 years and over
People
641 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06319820
Phase 3Taking people
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Where
Bunkyō City, Funabashi, Hakodate, Kawasaki, Minatoku, Sakura, Yokohama
Age
18 years and over
People
220 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06919965 · EU 2024-519493-39-00
Phase 1Taking people
A Study of GEN1106 in Participants With Solid Tumors
Where
Chuo Ku
Age
18 years and over
People
103 worldwide
Run by
Genmab
See details and how to joinNCT07416123 · EU 2025-523760-21-00
Phase 3Taking people
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Where
Bunkyo, Fukuoka, Gifu, Hirosaki, Kashihara, Kawasaki, Kita-gun, Kobe, Koto, Kyoto, Nagoya, Sagamihara, Sakai, Sapporo, Tōon, Tsukuba
Age
18 years and over
People
590 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07419295 · EU 2024-520014-22-00
Phase 1Taking people
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
Where
Kashiwa
Age
18 years and over
People
156 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07660055
Phase 2Taking people
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Where
Bunkyo-ku, Gifu, Kawasaki, Kobe, Koto-ku, Kyoto, Osaka, Tsukuba, Ube
Age
18 years and over
People
240 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07475806
Phase 3Taking people
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Where
Bunkyo-ku, Fukuoka, Hiroshima, Hitachi, Kashihara, Kawasaki, Kobe, Matsuyama, Nagakute, Nagoya, Nankoku, Narita, Tokyo, Tsu, Tsukuba, Wakayama, Yokohama
Age
18 years and over
People
454 worldwide
Run by
Ferring Pharmaceuticals
See details and how to joinNCT06510374 · EU 2024-512029-10-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Hidaka, Kagoshima, Kanagawa, Kashiwa-shi, Matsuyama, Nagaizumi-chō, Nagoya, Osakasayama-Shi, Saitama, Tokyo, Yokohama
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Chuo Ku, Kashiwa, Koto-ku, Matsuyama, Nagaizumi-chō, Nagoya, Ōsaka-sayama, Saitama
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 1/2Taking people
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Where
Chuo Ku, Hirakata-shi, Kashiwa-shi, Koto-ku
Age
18 years and over
People
428 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07287995
Phase 1/2Taking people
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Where
Fukuoka, Shinjuku-ku, Yamagata
Age
18 years and over
People
132 worldwide
Run by
Pfizer
See details and how to joinNCT07421700 · EU 2025-523523-21-00
Phase 3Taking people
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Where
Chūōku, Fukuoka, Hirosaki, Kanazawa, Kashiwa, Kawasaki, Kita-ku, Kobe, Kōtoku, Kyoto, Matsuyama, Nagoya, Niigata, Osaka, Otashi, Sapporo, Sendai, Shiwa-gun Yahaba-cho, Tokushima, Tsukuba
Age
18 years and over
People
450 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07218380 · EU 2025-522855-25-00
Phase 2Taking people
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Where
Amagasaki-shi, Fuji-shi, Fukuoka, Funabashi-shi, Hitachi-shi, Komaki-shi, Nagoya, Niigata, Osaka, Sakura-shi, Toyama, Yokohama
Age
18 years and over
People
131 worldwide
Run by
Protara Therapeutics
See details and how to joinNCT05951179
Phase 2/3Taking people
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Where
Bunkyō City, Fukuoka, Hirosaki-shi, Kanazawa, Kawasaki, Kōtoku, Kumamoto, Kyoto, Nagoya, Niigata, Okayama, Osaka, Osakasayama-shi, Sapporo, Shinjuku-ku, Toyama, Tsukuba, Ube-shi
Age
18 years and over
People
630 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT07129993
Phase 1/2Taking people
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Where
Kashiwa
Age
18 years and over
People
1,109 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT04895709
Phase 2/3Taking people
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Where
Bunkyo-ku, Kawasaki, Koto-ku, Toyoma
Age
18 years and over
People
470 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07106762
Phase 2Taking people
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Where
Kashiwa-shi, Koto-ku, Osaka, Sapporo, Suita-shi, Tokushima
Age
18 years and over
People
372 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT04879329 · EU 2022-500030-28-01
Phase 3Taking people
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Where
Fukuoka, Hamamatsu, Hirosaki-shi, Kanazawa, Kashihara-shi, Kawasaki-shi, Kita-gun, Kobe, Kōtoku, Kumamoto, Nagasaki, Nagoya, Osaka, Toyama, Tsukuba
Age
18 years and over
People
915 worldwide
Run by
AstraZeneca
See details and how to joinNCT07720284
No phaseTaking people
Predicting BCG Response
Where
Kyoto
Age
18 years to 90 years
People
400 worldwide
Run by
Cedars-Sinai Medical Center
See details and how to joinNCT04564781
No phaseTaking people
A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder Cancer
Where
Kyoto
Age
18 years and over
People
300 worldwide
Run by
Cedars-Sinai Medical Center
See details and how to joinNCT03193515
No phaseTaking people
A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer
Where
Nara
Age
18 years to 90 years
People
900 worldwide
Run by
Cedars-Sinai Medical Center
See details and how to joinNCT03193541
Phase 1/2Taking people
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Where
Chuo Ku, City
Age
18 years and over
People
27 worldwide
Run by
Tanabe Pharma America, Inc.
See details and how to joinNCT06943521